Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC)

被引：1
作者：
Jiang, Di Maria
Sim, Hao-Wen
Siu, Lillian L.
Shapiro, Jeremy David
Liu, Geoffrey
Price, Timothy Jay
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699
引用
收藏
页数：1
相关论文
共 50 条
[41]   Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy. [J].
Miyamoto, Yuji ;
Stintzing, Sebastian ;
Heinemann, Volker ;
Zhang, Wu ;
Cao, Shu ;
Okazaki, Satoshi ;
Berger, Martin D. ;
Suenaga, Mitsukuni ;
Schirripa, Marta ;
Soni, Shivani ;
Matsusaka, Satoshi ;
Ning, Yan ;
Yang, Dongyun ;
Gopez, Roel ;
Melendez, Elizabeth ;
Hanna, Diana L. ;
Barzi, Afsaneh ;
Baba, Hideo ;
Lenz, Heinz-Josef .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42]   Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial [J].
Folprecht, G. ;
Nowacki, M. ;
Lang, I. ;
Cascinu, S. ;
Shchepotin, I. ;
Maurel, J. ;
Rougier, P. ;
Cunningham, D. ;
Zubel, A. ;
Van Cutsem, E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[43]   Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience [J].
Yang, D. ;
Pohl, A. ;
Zhang, W. ;
Lurje, G. ;
Ning, Y. ;
El-Khoueiry, A. ;
Khambata-Ford, S. ;
Langer, C. ;
Iqbal, S. ;
Lenz, H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[44]   Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC) [J].
Ichikawa, W. ;
Mogushi, K. ;
Lenz, H-J. ;
Zhang, W. ;
Tsuji, A. ;
Takahashi, T. ;
Denda, T. ;
Shimada, K. ;
Kochi, M. ;
Nakamura, M. ;
Kotaka, M. ;
Segawa, Y. ;
Lafleur, B. ;
Luecke, J. ;
Thompson, D. ;
Moran, M. ;
Astrow, S. H. ;
Hsiang, J. ;
Fujii, M. ;
Sunakawa, Y. .
ANNALS OF ONCOLOGY, 2017, 28
[45]   Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study [J].
Renouf, D. J. ;
Lim, H. J. ;
Speers, C. ;
Villa, D. ;
Gill, S. ;
Blanke, C. D. ;
O'Reilly, S. E. ;
Kennecke, H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[46]   Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). [J].
Ruzzo, Annamaria ;
Torsello, Angela ;
Sperduti, Isabella ;
Melucci, Elisa ;
Giacomini, Elisa ;
Mottolese, Marcella ;
Fiorino, Roberta ;
Zeuli, Massimo ;
Pescarmona, Edoardo ;
Magnani, Mauro ;
Cognetti, Francesco ;
Garufi, Carlo .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[47]   Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) [J].
Torsello, A. ;
Ruzzo, A. ;
Sperduti, I. ;
Melucci, E. ;
Giacomini, E. ;
Mottolese, M. ;
Fiorino, R. ;
Zeuli, M. ;
Pescarmona, E. ;
Magnani, M. ;
Cognetti, F. ;
Garufi, C. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 :S398-S398
[48]   Multiple treatment lines and prognosis for metastatic colorectal (mCRC) patients (pts) [J].
Rosanova, M. ;
De Falco, S. ;
Attademo, L. ;
Fiore, G. ;
De Stefano, A. ;
Maddalena, C. ;
De Placido, S. ;
Carlomagno, C. .
ANNALS OF ONCOLOGY, 2017, 28
[49]   Effects of capecitabine (X) an quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC). [J].
Beato, CAM ;
Federico, MH ;
Van Eyll, B ;
Cabral, S ;
Perdicaris, M ;
Skare, NG ;
Lago, S ;
Carvalho, MP ;
Moura, GL ;
Duarte, RC .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :758S-758S
[50]   CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) [J].
Bounedjar, A. ;
Smail, F. .
ANNALS OF ONCOLOGY, 2010, 21 :67-68
12345